uniQure N.V. $QURE Shares Sold by Readystate Asset Management LP

Readystate Asset Management LP lessened its holdings in shares of uniQure N.V. (NASDAQ:QURE) by 20.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 400,989 shares of the biotechnology company’s stock after selling 103,713 shares during the period. Readystate Asset Management LP owned approximately 0.58% of uniQure worth $18,470,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Woodline Partners LP grew its stake in uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares during the last quarter. Legal & General Group Plc purchased a new stake in uniQure in the second quarter valued at about $497,000. Marshall Wace LLP boosted its holdings in uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after acquiring an additional 163,749 shares in the last quarter. California State Teachers Retirement System acquired a new stake in uniQure in the second quarter worth about $540,000. Finally, Ameriprise Financial Inc. grew its stake in shares of uniQure by 38.6% during the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after acquiring an additional 212,218 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

Insider Buying and Selling at uniQure

In other news, Director Jack Kaye sold 21,167 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $46.44, for a total value of $982,995.48. Following the sale, the director owned 25,996 shares in the company, valued at $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Kapusta sold 21,082 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $45.16, for a total transaction of $952,063.12. Following the transaction, the chief executive officer directly owned 519,227 shares of the company’s stock, valued at approximately $23,448,291.32. This trade represents a 3.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 385,584 shares of company stock valued at $16,737,722. 4.65% of the stock is currently owned by insiders.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $44.50 on Monday. uniQure N.V. has a 52-week low of $8.73 and a 52-week high of $71.50. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -11.10 and a beta of 0.94. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $44.30 and a 200-day moving average price of $30.41.

uniQure (NASDAQ:QURE) last released its earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%.The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same period last year, the firm earned ($0.69) EPS. Equities analysts predict that uniQure N.V. will post -3.82 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on QURE. The Goldman Sachs Group upped their price objective on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a report on Thursday, June 18th. Barclays lowered their target price on shares of uniQure from $65.00 to $60.00 and set an “overweight” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, William Blair assumed coverage on shares of uniQure in a report on Wednesday, September 2nd. They issued an “outperform” rating for the company. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $65.00.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.